Thomas Cueni has led IFPMA since 2017, during which time he has been instrumental in establishing cross sectoral programs designed to tackle the biggest global health challenges. This includes establishing the $1bn AMR Action Fund to support the development of new antibiotics; as Chair of the AMR Alliance; as a member of the Board of City Cancer Challenge; and as the industry’s representative on the Access to COVID-19 Tools (ACT) Accelerator. Leading the IFPMA through the COVID-19 pandemic, Thomas galvanised the industry to develop the Berlin Declaration – the pharmaceutical industry’s blueprint to deliver equitable access to vaccines, treatments, and diagnostics in future pandemics. Thomas is Chair of the Business at OECD Health Committee and serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. He is also a member of the Business Advisory Group established by the Director General of the World Trade Organization. Prior to joining IFPMA, Thomas was Secretary General of Interpharma, the trade association representing Switzerland’s research-based pharmaceutical industry; Secretary of the Dolder Group, precursor of what’s now the BCR; and served on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Thomas began his career as a journalist, as London correspondent for the Basler Zeitung and Der Bund, before serving as a Swiss diplomat in Paris (OECD) and Vienna (IAEA, UNIDO). Thomas has a master’s degree in economics from the University of Basel and another in politics from the London School of Economics. He also studied at the Geneva Graduate Institute for International Studies.